Literature DB >> 28107692

RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Ayuna Hattori1, Daniel McSkimming1, Natarajan Kannan1, Takahiro Ito2.   

Abstract

FLT3 is frequently mutated and overexpressed in acute myelogenous leukemia (AML) and other hematologic malignancies. Although signaling events downstream of FLT3 receptor tyrosine kinase have been studied in depth, molecular mechanisms of how FLT3 expression is regulated at the post-transcriptional level in particular remain elusive. In this study, we investigated the roles of an RNA binding protein MSI2 as a regulator of FLT3 expression. MSI2 and FLT3 are significantly co-regulated in human AML and chronic myelogenous leukemia in blast crisis (BC-CML). Genetic loss of MSI2 leads to down-regulation of the FLT3 receptor in both AML and BC-CML cells and concomitant impairment of clonogenic growth potential. Furthermore, we demonstrate that MSI2 protein is physically bound to FLT3 mRNA transcripts, suggesting post-transcriptional control of FLT3 expression. Collectively, these results reveal a novel mode of FLT3 regulation essential for leukemia growth, which may aid in designing a targeted therapy to treat human myeloid leukemia.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute myelogenous leukemia; Chronic myelogenous leukemia; FLT3; Post-transcriptional regulation; RNA binding proteins

Mesh:

Substances:

Year:  2017        PMID: 28107692      PMCID: PMC5508866          DOI: 10.1016/j.leukres.2017.01.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  53 in total

1.  An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity.

Authors:  Kristin J Hope; Sonia Cellot; Stephen B Ting; Tara MacRae; Nadine Mayotte; Norman N Iscove; Guy Sauvageau
Journal:  Cell Stem Cell       Date:  2010-07-02       Impact factor: 24.633

2.  A conserved three-nucleotide core motif defines Musashi RNA binding specificity.

Authors:  N Ruth Zearfoss; Laura M Deveau; Carina C Clingman; Eric Schmidt; Emily S Johnson; Francesca Massi; Sean P Ryder
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

3.  All hematopoietic cells develop from hematopoietic stem cells through Flk2/Flt3-positive progenitor cells.

Authors:  Scott W Boyer; Aaron V Schroeder; Stephanie Smith-Berdan; E Camilla Forsberg
Journal:  Cell Stem Cell       Date:  2011-07-08       Impact factor: 24.633

4.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

5.  The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia.

Authors:  Lars Palmqvist; Bob Argiropoulos; Nicolas Pineault; Carolina Abramovich; Laura M Sly; Gerald Krystal; Adrian Wan; R Keith Humphries
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

6.  FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates.

Authors:  C Lavagna-Sévenier; S Marchetto; D Birnbaum; O Rosnet
Journal:  Leukemia       Date:  1998-03       Impact factor: 11.528

7.  Leukemia stem cells in a genetically defined murine model of blast-crisis CML.

Authors:  Sarah J Neering; Timothy Bushnell; Selcuk Sozer; John Ashton; Randall M Rossi; Pin-Yi Wang; Deborah R Bell; David Heinrich; Andrea Bottaro; Craig T Jordan
Journal:  Blood       Date:  2007-06-29       Impact factor: 22.113

8.  Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of normal hematopoietic and leukemic stem cells.

Authors:  Lan-Lan Smith; Jenny Yeung; Bernd B Zeisig; Nikolay Popov; Ivo Huijbers; Josephine Barnes; Amanda J Wilson; Erdogan Taskesen; Ruud Delwel; Jesús Gil; Maarten Van Lohuizen; Chi Wai Eric So
Journal:  Cell Stem Cell       Date:  2011-06-03       Impact factor: 24.633

9.  Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions.

Authors:  Eric M Pietras; Damien Reynaud; Yoon-A Kang; Daniel Carlin; Fernando J Calero-Nieto; Andrew D Leavitt; Joshua M Stuart; Berthold Göttgens; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2015-06-18       Impact factor: 24.633

10.  BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis.

Authors:  Frederik Otzen Bagger; Damir Sasivarevic; Sina Hadi Sohi; Linea Gøricke Laursen; Sachin Pundhir; Casper Kaae Sønderby; Ole Winther; Nicolas Rapin; Bo T Porse
Journal:  Nucleic Acids Res       Date:  2015-10-26       Impact factor: 16.971

View more
  9 in total

Review 1.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

2.  Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples.

Authors:  Ayelet Alpert; Ornit Nahman; Elina Starosvetsky; Michal Hayun; Tyler J Curiel; Yishai Ofran; Shai S Shen-Orr
Journal:  Cell Syst       Date:  2021-10-07       Impact factor: 11.091

3.  Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.

Authors:  Elizabeth Heyes; Luisa Schmidt; Gabriele Manhart; Thomas Eder; Ludovica Proietti; Florian Grebien
Journal:  Leukemia       Date:  2021-02-23       Impact factor: 11.528

Review 4.  RNA Regulators in Leukemia and Lymphoma.

Authors:  Camila Prieto; Michael G Kharas
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

5.  Evasion of regulatory phosphorylation by an alternatively spliced isoform of Musashi2.

Authors:  Melanie C MacNicol; Chad E Cragle; F Kennedy McDaniel; Linda L Hardy; Yan Wang; Karthik Arumugam; Yasir Rahmatallah; Galina V Glazko; Ania Wilczynska; Gwen V Childs; Daohong Zhou; Angus M MacNicol
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

6.  TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.

Authors:  Tatiana Erazo; Chiara M Evans; Daniel Zakheim; Karen L Chu; Alice Yunsi Refermat; Zahra Asgari; Xuejing Yang; Mariana Da Silva Ferreira; Sanjoy Mehta; Marco Vincenzo Russo; Andrea Knezevic; Xi-Ping Zhang; Zhengming Chen; Myles Fennell; Ralph Garippa; Venkatraman Seshan; Elisa de Stanchina; Olena Barbash; Connie Lee Batlevi; Christina S Leslie; Ari M Melnick; Anas Younes; Michael G Kharas
Journal:  Nat Commun       Date:  2022-09-27       Impact factor: 17.694

7.  Mutational patterns and clonal evolution from diagnosis to relapse in pediatric acute lymphoblastic leukemia.

Authors:  Shumaila Sayyab; Anders Lundmark; Malin Larsson; Markus Ringnér; Sara Nystedt; Yanara Marincevic-Zuniga; Katja Pokrovskaja Tamm; Jonas Abrahamsson; Linda Fogelstrand; Mats Heyman; Ulrika Norén-Nyström; Gudmar Lönnerholm; Arja Harila-Saari; Eva C Berglund; Jessica Nordlund; Ann-Christine Syvänen
Journal:  Sci Rep       Date:  2021-08-06       Impact factor: 4.379

8.  Deciphering Key Pharmacological Pathways of Qingdai Acting on Chronic Myeloid Leukemia Using a Network Pharmacology-Based Strategy.

Authors:  Huayao Li; Lijuan Liu; Cun Liu; Jing Zhuang; Chao Zhou; Jing Yang; Chundi Gao; Gongxi Liu; Qingliang Lv; Changgang Sun
Journal:  Med Sci Monit       Date:  2018-08-15

9.  2-Methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223/Fms-like tyrosine kinase 3/phosphatidylinositol-3 kinase/protein kinase B axis.

Authors:  Suwei Zhang; Hanhui Yu; Jiazhen Li; Jingru Fan; Jingchao Chen
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.